Drug Profile
Research programme: neurological disorders therapeutics - AstraZneca/Berg Pharma
Latest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator AstraZeneca; Berg Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Neurological-disorders in USA
- 28 Aug 2017 AstraZeneca and Berg Pharma enter into a collaborative research agreement for the discovery and development of neurological disorders therapeutics
- 28 Aug 2017 Early research in Neurological disorders in USA (unspecified route)